‌

US Patent 10654844 Dual mechanism inhibitors for the treatment of disease

Patent 10654844 was granted and assigned to Aerie Pharmaceuticals on May, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Aerie Pharmaceuticals

0

Current Assignee

Aerie Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

May 19, 2020

0

Patent Application Number

164352540

Date Filed

June 7, 2019

0

Patent Citations

US Patent 10174017 Dual mechanism inhibitors for the treatment of disease

US Patent 10112920 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds

US Patent 10316029 Dual mechanism inhibitors for the treatment of disease

Patent Citations Received

US Patent 12018012 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

0

US Patent 11312700 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

0

US Patent 11427563 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

US Patent 11891376 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

0

US Patent 11020385 Combination therapy

US Patent 11590123 Ophthalmic compositions

US Patent 11618748 Dual mechanism inhibitors for the treatment of disease

0

US Patent 11707460 Ophthalmic compositions

0

Patent Primary Examiner

D Margaret M Seaman

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10654844 Dual mechanism inhibitors for the treatment of disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.